Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Department of Surgery, Oncology Subdivision, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
F1000Res. 2021 Sep 27;10:975. doi: 10.12688/f1000research.53539.2. eCollection 2021.
Cancer patients are considered susceptible to coronavirus disease (COVID-19) due to an immunosuppressive state. This study determined the prevalence of cancer as a comorbid in COVID-19 patients, severe events, case fatality rate, history of anticancer therapy associated with severe events, and type of cancer in cancer patients with COVID-19 in the world. This study used a meta-analysis study approach, sourcing studies from various countries related to cancer and COVID-19. Inclusion and exclusion criteria were established to select studies. A PRISMA flowchart was presented to assess the selection process. Data from inclusion studies were analyzed using Review Manager 5.4. The prevalence of cancer as a comorbid in COVID-19 patients was 4.63% (95% CI, 3.78-5.49%) worldwide. The lowest prevalence was the Asian study group with 2.36% (95% CI, 1.86-2.87%) and the highest prevalence was the European study group with 10.93% (95% CI, 6.62-15.24%). About 43.26% (95% CI, 34.71-51.80%) of COVID-19 patients with cancer as comorbid experienced severe events of COVID-19. In total, 58.13% (95% CI, 42.79-73.48%) of COVID-19 patients with cancer as a comorbid who in the last month had a history of anticancer therapy experienced severe events. The prevalence of lung cancer in cancer patients with COVID-19 was 20.23% (95% CI, 7.67-32.78%). Forest plots are also presented related to the results of meta-analysis research. High prevalence of cancer as a comorbid among COVID-19 patients indicates the susceptibility of cancer patients to SARS-CoV-2 infection. Cancer as a comorbid in COVID-19 patients and use of anticancer therapy increase severe events of COVID-19.
由于免疫抑制状态，癌症患者被认为易感染冠状病毒病（COVID-19）。本研究旨在确定全球 COVID-19 患者中癌症合并症的患病率、严重事件、病死率、与严重事件相关的抗癌治疗史以及癌症患者的癌症类型。本研究采用荟萃分析研究方法，从与癌症和 COVID-19 相关的多个国家获取研究。建立了纳入和排除标准来选择研究。提出了 PRISMA 流程图来评估选择过程。使用 Review Manager 5.4 分析纳入研究的数据。全球范围内，COVID-19 患者合并症癌症的患病率为 4.63%（95%CI，3.78-5.49%）。亚洲研究组的患病率最低，为 2.36%（95%CI，1.86-2.87%），欧洲研究组的患病率最高，为 10.93%（95%CI，6.62-15.24%）。约 43.26%（95%CI，34.71-51.80%）的 COVID-19 合并癌症患者发生 COVID-19 严重事件。共有 58.13%（95%CI，42.79-73.48%）的 COVID-19 合并癌症患者在过去一个月内有抗癌治疗史发生严重事件。COVID-19 合并癌症患者中肺癌的患病率为 20.23%（95%CI，7.67-32.78%）。还呈现了与荟萃分析研究结果相关的森林图。COVID-19 患者中癌症合并症的高患病率表明癌症患者易感染 SARS-CoV-2。COVID-19 患者中癌症合并症和抗癌治疗的使用增加了 COVID-19 的严重事件。
